missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ INSR alpha Chimeric Recombinant Rabbit Monoclonal Antibody (83-14)

Description
Specificity: Recognises the extracellular domain of the Insulin Receptor alpha. Amino acids 469-592 (exon 7 and 8) of Insulin Receptor alpha.
Biological actions of insulin and IGF-1 are mediated by their respective cell surface receptor tyrosine kinases that regulate multiple signaling pathways through activation of a series of phosphorylation cascades. The insulin receptor. Insulin/IGF-1 binding to the extracellular domain leads to autophosphorylation of downstream target proteins. These two receptors differ in sequence in regions that confer specificity for the designated ligand as well as in certain intracellular signaling domains, resulting in significant differences in the functional consequences of activation of each receptor. Defects in IR are the cause of various insulin resistance syndromes and IGF-1R defects may cause some forms of growth retardation. Both these signaling cascades are also important for the development of cancer.
Specifications
Specifications
| Antigen | INSR alpha Chimeric |
| Applications | ELISA, Flow Cytometry, Immunohistochemistry, Immunoprecipitation, Western Blot |
| Classification | Recombinant Monoclonal |
| Clone | 83-14 |
| Concentration | 1 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 0.02% ProClin 300 |
| Gene | INSR |
| Gene Accession No. | P06213 |
| Gene Alias | 4932439J01Rik; CD220; CD220 beta; D630014A15Rik; DAF-2; HHF5; INSR; insulin receptor; insulin receptor (INSR); insulin receptor precursor; insulin receptor preproprotein; Insulin receptor subunit alpha; Insulin receptor subunit beta; IR; IR alpha; IR beta; ir-A; IR-B |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?